Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
GlobeNewswire, Inc.
Company announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GlobeNewswire, Inc.
Company announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 28, 2026 – Zealand Pharma...
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related...
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
GlobeNewswire, Inc.
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic...
Zealand Pharma – Notification of holding of treasury shares
GlobeNewswire, Inc.
Company announcement – No. 42 / 2026 Zealand Pharma – Notification of holding of treasury shares Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology...
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
GlobeNewswire, Inc.
Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Food as Medicine Market to Reach USD 400.81 Billion by 2031, Growing at a CAGR of 9.5% — MarketsandMarkets™
GlobeNewswire, Inc.
Delray Beach, FL , Aug. 24, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ estimates the global food as medicine Industry to grow from USD 254.15 billion in 2026 to USD 400.81 billion by 2031, registering a CAGR of 9.5% during the forecast period....
A New Framework Establishes 'The Hallmarks of Skeletal Muscle Health'
EIN Presswire
An international consortium of experts outlines a unifying conceptual framework to transform precision diagnostics, therapeutics, and healthy aging strategies TORONTO, CANADA, August 20, 2026 /EINPresswire.com/ -- Today, an international team of...
UNCF Announces Historic $12 Million Gift from The James and Judith K. Dimon Foundation to Strengthen HBCU Endowments and Expand Pathways in Healthcare and Education
GlobeNewswire, Inc.
Washington, DC, Aug. 20, 2026 (GLOBE NEWSWIRE) -- UNCF announced The Dimon Fund to Advance Economic Opportunity, a historic $12 million gift from The James and Judith K. Dimon Foundation to strengthen the long-term sustainability of historically...
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
GlobeNewswire, Inc.
Company announcement No. 40 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 33, 2026) Copenhagen, Denmark, August 17, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
First Chinese PD-1 Inhibitor Hetronifly® (serplulimab) Recommended by NICE for NHS Lung Cancer Care
EIN Presswire
UK's NICE recommends China's serplulimab (trade name in Europe: Hetronifly) for routine use within the National Health Service (NHS) in England and Wales SHANGHAI, CHINA, August 30, 2026 /EINPresswire.com/ -- A pioneering immune checkpoint...
Zealand Pharma Announces Financial Results for the First Half of 2026
GlobeNewswire, Inc.
Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of...
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
GlobeNewswire, Inc.
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its...
Ascendis Pharma Reports Second Quarter 2026 Financial Results
GlobeNewswire, Inc.
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® – Through July 31, more than 220 unique YUVIWEL patient enrollments in the U.S. – Substantial...
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
GlobeNewswire, Inc.
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing the use of SNIPR001 in a...
CIP and Thylander start construction of energy-integrated data centre in Denmark backed by PensionDanmark
GlobeNewswire, Inc.
One of the first major data centres to be wholly owned and operated by Danish companies is now being established in Esbjerg, in southern Denmark.
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
GlobeNewswire, Inc.
Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a...
WeRide Included in HKEX Tech 100 Index Following September 2026 Quarterly Review
GlobeNewswire, Inc.
HONG KONG, Aug. 31, 2026 (GLOBE NEWSWIRE) -- WeRide (Nasdaq: WRD, HKEX: 0800), a global leader in autonomous driving technology, today announced its inclusion as a constituent of the HKEX Tech 100 Index following the latest quarterly index review...
Rinn Pharma & Biopharma Expands European Research Collaboration Through NordicPharmaTrain Partnership
EIN Presswire
Rinn Pharma & Biopharma expanding collaborative research and training across the Nordic and European innovation landscape.
Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
GlobeNewswire, Inc.
Press Release – No. 14 / 2026 Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results Copenhagen, Denmark, August 6, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.